How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9352"
  ["article_id"]=>
  string(4) "9352"
  [1]=>
  string(96) "Harvard Dental and UCLA Medical Graduate Dr. Jacob Taylor Joins Center for Oral & Facial Surgery"
  ["article_title"]=>
  string(96) "Harvard Dental and UCLA Medical Graduate Dr. Jacob Taylor Joins Center for Oral & Facial Surgery"
  [2]=>
  string(150) "Dr. Jacob T. Taylor has joined the Center for Oral & Facial Surgery, the oldest and largest oral and maxillofacial surgery practice in San Diego Count"
  ["short_description"]=>
  string(150) "Dr. Jacob T. Taylor has joined the Center for Oral & Facial Surgery, the oldest and largest oral and maxillofacial surgery practice in San Diego Count"
  [3]=>
  string(152) "Dr. Jacob T. Taylor has joined the Center for Oral & Facial Surgery, the oldest and largest oral and maxillofacial surgery practice in San Diego County."
  ["description"]=>
  string(152) "Dr. Jacob T. Taylor has joined the Center for Oral & Facial Surgery, the oldest and largest oral and maxillofacial surgery practice in San Diego County."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(165) "https://www.globenewswire.com/news-release/2024/08/22/2934374/0/en/Harvard-Dental-and-UCLA-Medical-Graduate-Dr-Jacob-Taylor-Joins-Center-for-Oral-Facial-Surgery.html"
  ["blog_url"]=>
  string(165) "https://www.globenewswire.com/news-release/2024/08/22/2934374/0/en/Harvard-Dental-and-UCLA-Medical-Graduate-Dr-Jacob-Taylor-Joins-Center-for-Oral-Facial-Surgery.html"
  [15]=>
  string(19) "2024-08-22 23:00:00"
  ["add_date"]=>
  string(19) "2024-08-22 23:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Harvard Dental and UCLA Medical Graduate Dr. Jacob Taylor Joins Center for Oral & Facial S

Dr. Jacob T. Taylor has joined the Center for Oral & Facial Surgery, the oldest and largest oral and maxillofacial surge

array(40) {
  [0]=>
  string(4) "9387"
  ["article_id"]=>
  string(4) "9387"
  [1]=>
  string(49) "What does the future look like for wearable tech?"
  ["article_title"]=>
  string(49) "What does the future look like for wearable tech?"
  [2]=>
  string(158) "The world of medical technology is constantly changing, and innovation is key. But there's always room for improvement. Wouldn't it be great if these "
  ["short_description"]=>
  string(158) "The world of medical technology is constantly changing, and innovation is key. But there's always room for improvement. Wouldn't it be great if these "
  [3]=>
  string(223) "The world of medical technology is constantly changing, and innovation is key. But there's always room for improvement. Wouldn't it be great if these devices were smaller, more comfortable, and even more functional?"
  ["description"]=>
  string(223) "The world of medical technology is constantly changing, and innovation is key. But there's always room for improvement. Wouldn't it be great if these devices were smaller, more comfortable, and even more functional?"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(132) "https://www.medicalplasticsnews.com/medical-plastics-industry-insights/latest-medical-plastics-insights/the-future-of-wearable-tech/"
  ["blog_url"]=>
  string(132) "https://www.medicalplasticsnews.com/medical-plastics-industry-insights/latest-medical-plastics-insights/the-future-of-wearable-tech/"
  [15]=>
  string(19) "2024-08-22 23:00:00"
  ["add_date"]=>
  string(19) "2024-08-22 23:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:32"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:32"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

What does the future look like for wearable tech?

The world of medical technology is constantly changing, and innovation is key. But there's always room for improveme

array(40) {
  [0]=>
  string(4) "9324"
  ["article_id"]=>
  string(4) "9324"
  [1]=>
  string(72) "FDA Fleshes Out Policy on Predetermined Change Control Plans for Devices"
  ["article_title"]=>
  string(72) "FDA Fleshes Out Policy on Predetermined Change Control Plans for Devices"
  [2]=>
  string(149) "&#nl        The FDA outlined its proposed policy on predetermined change control plans (PCCPs) for medical devices in a new draft guidance.&#nl      "
  ["short_description"]=>
  string(149) "&#nl        The FDA outlined its proposed policy on predetermined change control plans (PCCPs) for medical devices in a new draft guidance.&#nl      "
  [3]=>
  string(149) "&#nl        The FDA outlined its proposed policy on predetermined change control plans (PCCPs) for medical devices in a new draft guidance.&#nl      "
  ["description"]=>
  string(149) "&#nl        The FDA outlined its proposed policy on predetermined change control plans (PCCPs) for medical devices in a new draft guidance.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(112) "https://www.fdanews.com/articles/214039-fda-fleshes-out-policy-on-predetermined-change-control-plans-for-devices"
  ["blog_url"]=>
  string(112) "https://www.fdanews.com/articles/214039-fda-fleshes-out-policy-on-predetermined-change-control-plans-for-devices"
  [15]=>
  string(19) "2024-08-22 22:55:46"
  ["add_date"]=>
  string(19) "2024-08-22 22:55:46"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:04"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Fleshes Out Policy on Predetermined Change Control Plans for Devices

&#nl The FDA outlined its proposed policy on predetermined change control plans (PCCPs) for medical devices in a 

array(40) {
  [0]=>
  string(4) "9429"
  ["article_id"]=>
  string(4) "9429"
  [1]=>
  string(64) "The newest member of the health system C-suite? Chief AI Officer"
  ["article_title"]=>
  string(64) "The newest member of the health system C-suite? Chief AI Officer"
  [2]=>
  string(150) "Beyond overseeing the implementation of AI projects, CAIOs consider broader implications, such as changes to operations and culture. And they aim to e"
  ["short_description"]=>
  string(150) "Beyond overseeing the implementation of AI projects, CAIOs consider broader implications, such as changes to operations and culture. And they aim to e"
  [3]=>
  string(239) "Beyond overseeing the implementation of AI projects, CAIOs consider broader implications, such as changes to operations and culture. And they aim to ensure AI systems are developed and deployed ethically, transparently and responsibly.&#nl"
  ["description"]=>
  string(239) "Beyond overseeing the implementation of AI projects, CAIOs consider broader implications, such as changes to operations and culture. And they aim to ensure AI systems are developed and deployed ethically, transparently and responsibly.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(90) "https://www.healthcareitnews.com/news/newest-member-health-system-c-suite-chief-ai-officer"
  ["blog_url"]=>
  string(90) "https://www.healthcareitnews.com/news/newest-member-health-system-c-suite-chief-ai-officer"
  [15]=>
  string(19) "2024-08-22 22:49:00"
  ["add_date"]=>
  string(19) "2024-08-22 22:49:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:43"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

The newest member of the health system C-suite? Chief AI Officer

Beyond overseeing the implementation of AI projects, CAIOs consider broader implications, such as changes to operations 

array(40) {
  [0]=>
  string(4) "9506"
  ["article_id"]=>
  string(4) "9506"
  [1]=>
  string(45) "China greenlight for Innovent’s Dupert"
  ["article_title"]=>
  string(45) "China greenlight for Innovent’s Dupert"
  [2]=>
  string(159) "China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatme"
  ["short_description"]=>
  string(159) "China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatme"
  [3]=>
  string(306) "China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy."
  ["description"]=>
  string(306) "China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologics’ Dupert (fulzerasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(69) "https://www.thepharmaletter.com/china-greenlight-for-innovents-dupert"
  ["blog_url"]=>
  string(69) "https://www.thepharmaletter.com/china-greenlight-for-innovents-dupert"
  [15]=>
  string(19) "2024-08-22 22:22:42"
  ["add_date"]=>
  string(19) "2024-08-22 22:22:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

China greenlight for Innovent’s Dupert

China's National Medical Products Administration (NMPA) has approved domestic biopharma firm Innovent Biologicsâ€

array(40) {
  [0]=>
  string(4) "9507"
  ["article_id"]=>
  string(4) "9507"
  [1]=>
  string(58) "Lilly boosts Oblique collab to focus on antibody discovery"
  ["article_title"]=>
  string(58) "Lilly boosts Oblique collab to focus on antibody discovery"
  [2]=>
  string(152) "Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma giant Eli Lilly (NYSE: LLY).&#nl"
  ["short_description"]=>
  string(152) "Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma giant Eli Lilly (NYSE: LLY).&#nl"
  [3]=>
  string(152) "Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma giant Eli Lilly (NYSE: LLY).&#nl"
  ["description"]=>
  string(152) "Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma giant Eli Lilly (NYSE: LLY).&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(104) "https://www.thepharmaletter.com/biotechnology/lilly-boosts-oblique-collab-to-focus-on-antibody-discovery"
  ["blog_url"]=>
  string(104) "https://www.thepharmaletter.com/biotechnology/lilly-boosts-oblique-collab-to-focus-on-antibody-discovery"
  [15]=>
  string(19) "2024-08-22 22:12:43"
  ["add_date"]=>
  string(19) "2024-08-22 22:12:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lilly boosts Oblique collab to focus on antibody discovery

Stockholm-based biotechnology firm Oblique Therapeutics has announced an expanded research collaboration with US pharma 

array(40) {
  [0]=>
  string(4) "9527"
  ["article_id"]=>
  string(4) "9527"
  [1]=>
  string(62) "Breaking News: Lecanemab approved in UK but unavailable on NHS"
  ["article_title"]=>
  string(62) "Breaking News: Lecanemab approved in UK but unavailable on NHS"
  [2]=>
  string(154) "Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-"
  ["short_description"]=>
  string(154) "Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-"
  [3]=>
  string(183) "Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-stage Alzheimerâs disease."
  ["description"]=>
  string(183) "Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-stage Alzheimerâs disease."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(165) "https://www.biopharma-reporter.com/Article/2024/08/22/uk-s-alzheimer-s-drug-lecanemab-approved-not-covered-by-nhs?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(165) "https://www.biopharma-reporter.com/Article/2024/08/22/uk-s-alzheimer-s-drug-lecanemab-approved-not-covered-by-nhs?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-22 22:10:00"
  ["add_date"]=>
  string(19) "2024-08-22 22:10:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:38"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Breaking News: Lecanemab approved in UK but unavailable on NHS

Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a sign

array(40) {
  [0]=>
  string(4) "9508"
  ["article_id"]=>
  string(4) "9508"
  [1]=>
  string(65) "Russia to increase production of anti-Rhesus immunoglobulin drugs"
  ["article_title"]=>
  string(65) "Russia to increase production of anti-Rhesus immunoglobulin drugs"
  [2]=>
  string(150) "Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of thei"
  ["short_description"]=>
  string(150) "Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of thei"
  [3]=>
  string(247) "Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. "
  ["description"]=>
  string(247) "Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(97) "https://www.thepharmaletter.com/russia-to-increase-production-of-anti-rhesus-immunoglobulin-drugs"
  ["blog_url"]=>
  string(97) "https://www.thepharmaletter.com/russia-to-increase-production-of-anti-rhesus-immunoglobulin-drugs"
  [15]=>
  string(19) "2024-08-22 21:36:43"
  ["add_date"]=>
  string(19) "2024-08-22 21:36:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Russia to increase production of anti-Rhesus immunoglobulin drugs

Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs 

array(40) {
  [0]=>
  string(4) "9509"
  ["article_id"]=>
  string(4) "9509"
  [1]=>
  string(50) "BridgeBio launches another new company, GondolaBio"
  ["article_title"]=>
  string(50) "BridgeBio launches another new company, GondolaBio"
  [2]=>
  string(150) "BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investo"
  ["short_description"]=>
  string(150) "BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investo"
  [3]=>
  string(157) "BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investors.&#nl"
  ["description"]=>
  string(157) "BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investors.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "81"
  ["rss_id"]=>
  string(2) "81"
  [14]=>
  string(95) "https://www.thepharmaletter.com/biotechnology/bridgebio-launches-another-new-company-gondolabio"
  ["blog_url"]=>
  string(95) "https://www.thepharmaletter.com/biotechnology/bridgebio-launches-another-new-company-gondolabio"
  [15]=>
  string(19) "2024-08-22 20:45:45"
  ["add_date"]=>
  string(19) "2024-08-22 20:45:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:25:18"
  ["create_at"]=>
  string(19) "2024-08-24 15:25:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

BridgeBio launches another new company, GondolaBio

BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a 

array(40) {
  [0]=>
  string(4) "9316"
  ["article_id"]=>
  string(4) "9316"
  [1]=>
  string(69) "SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK"
  ["article_title"]=>
  string(69) "SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK"
  [2]=>
  string(89) "The grant will support clinical trials of rare disease therapy for leukodystrophy&#nl&#nl"
  ["short_description"]=>
  string(89) "The grant will support clinical trials of rare disease therapy for leukodystrophy&#nl&#nl"
  [3]=>
  string(246) "
The grant will support clinical trials of rare disease therapy for leukodystrophy
&#nl
&#nl"
  ["description"]=>
  string(246) "
The grant will support clinical trials of rare disease therapy for leukodystrophy
&#nl
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(95) "https://pharmatimes.com/news/synaptixbio-awarded-2m-biomedical-catalyst-grant-from-innovate-uk/"
  ["blog_url"]=>
  string(95) "https://pharmatimes.com/news/synaptixbio-awarded-2m-biomedical-catalyst-grant-from-innovate-uk/"
  [15]=>
  string(19) "2024-08-22 20:13:47"
  ["add_date"]=>
  string(19) "2024-08-22 20:13:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:19:00"
  ["create_at"]=>
  string(19) "2024-08-24 15:19:00"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK

The grant will support clinical trials of rare disease therapy for leukodystrophy

&#nl

array(40) {
  [0]=>
  string(4) "9528"
  ["article_id"]=>
  string(4) "9528"
  [1]=>
  string(84) "First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1"
  ["article_title"]=>
  string(84) "First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1"
  [2]=>
  string(148) "ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients."
  ["short_description"]=>
  string(148) "ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients."
  [3]=>
  string(148) "ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients."
  ["description"]=>
  string(148) "ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(171) "https://www.biopharma-reporter.com/Article/2024/08/22/FDA-greenlights-first-CAR-T-therapy-for-multiple-sclerosis-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(171) "https://www.biopharma-reporter.com/Article/2024/08/22/FDA-greenlights-first-CAR-T-therapy-for-multiple-sclerosis-trials?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-22 19:38:00"
  ["add_date"]=>
  string(19) "2024-08-22 19:38:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:26:38"
  ["create_at"]=>
  string(19) "2024-08-24 15:26:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multi

array(40) {
  [0]=>
  string(4) "9409"
  ["article_id"]=>
  string(4) "9409"
  [1]=>
  string(56) "H1 Connect links doctors to global humanitarian missions"
  ["article_title"]=>
  string(56) "H1 Connect links doctors to global humanitarian missions"
  [2]=>
  string(154) "H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare "
  ["short_description"]=>
  string(154) "H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare "
  [3]=>
  string(220) "H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most."
  ["description"]=>
  string(220) "H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(161) "https://www.outsourcing-pharma.com/Article/2024/08/22/H1-partners-with-GRM-to-deliver-critical-aid-in-Ukraine?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(161) "https://www.outsourcing-pharma.com/Article/2024/08/22/H1-partners-with-GRM-to-deliver-critical-aid-in-Ukraine?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-08-22 17:50:00"
  ["add_date"]=>
  string(19) "2024-08-22 17:50:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:39"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

H1 Connect links doctors to global humanitarian missions

H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harne